The further loss of PTEN protein expression is significantly correlated with a decrease in overall survival (OS) and a reduction in the time it takes for brain metastases to arise in stage IIIB/C melanoma patients with BRAF (V600) mutations [41]. This evidence concerns the gene BRAF and melanoma.